Oral bisphosphonate compliance and persistence: a matter of choice? - Wikidata - wikimedia - TriplyDB

Oral bisphosphonate compliance and persistence: a matter of choice?

Oral bisphosphonate compliance and persistence: a matter of choice?

http://www.wikidata.org/entity/Q34472700

about

Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA The importance of physical function to people with osteoporosis Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).Clinical utility of denosumab for treatment of bone loss in men and women Risk of atypical femoral fracture during and after bisphosphonate use.Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study.Compliance to antifracture treatments in Tuscany: a regional survey based on institutional pharmaceutical dataset.Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy Can Alarming Improve Compliance with Weekly Bisphosphonate in Patients with Osteoporosis?Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.Impact of the training on the compliance and persistence of weekly bisphosphonate treatment in postmenopausal osteoporosis: a randomized controlled study.Partial adherence: a new perspective on health economic assessment in osteoporosis.Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.Adherence with medications used to treat osteoporosis: behavioral insights.Osteoporosis in older persons: current pharmacotherapy and future directions.Trends in and relation between hip fracture incidence and osteoporosis medication utilization and prices in Estonia in 2004-2015.Adherence to osteoporosis medicines in Estonia-a comprehensive 15-year retrospective prescriptions database study.Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter.Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid.GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.Prescribing Physical Activity for the Prevention and Treatment of Osteoporosis in Older Adults.How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study.

P2860

Q30988951-179F2755-3B7B-42FB-A132-E211C923C877 Q33563852-F64AE264-9602-4CD4-B4AE-C15FCCCC4E75 Q35077750-06707900-0FD2-4EAB-BC55-79F7EF8A3813 Q35092799-E418A16D-9251-455E-8603-DF0F1E53577F Q35197628-262822F9-552B-4121-9FA0-0A2B662C4C46 Q35707347-60D202DE-C973-4CCF-ADE3-79BF7FCC34EC Q35755661-7611AA7B-1BBD-4C97-AEAF-504A06099B5D Q36343783-FFEDC7F0-44AA-4DDE-AA23-34166B47EA1D Q36829073-084D5148-1A10-4F09-848E-9DA9AB4CE29D Q36989616-A95C38A7-7057-4467-AC30-D28A3904F221 Q37058784-D4E5228C-3717-4340-94CE-9595EEFD4C4A Q37147488-2E47608E-372C-4F70-869C-A6DA2FDFD28E Q37376275-64A78E3F-95AA-4C01-8E3E-066AA261342B Q37880657-5FB55A8E-E531-4AAE-8653-27BA8BCF1FE1 Q38073889-58DA4815-586A-46F8-A97A-21858C9F2AB1 Q38075457-508F446D-68C5-48AE-B15A-0DA3A536AF80 Q38124052-DAAB93E1-A89C-477F-8432-4FF149BBF11F Q38790108-DE1542FA-CF06-4C10-9F92-0910498CBF84 Q40148523-5FBADC85-A220-44C8-A9C6-24BFBEF2603F Q41704724-A13860B9-B9B4-498B-A6C9-873E1CA00F6C Q43749746-048AD876-A430-4C55-AD91-A13E02FA8A16 Q44452724-4B32DAF9-E911-4869-A508-005BC39E8D97 Q44892769-4530DEEF-AD2E-412A-86CE-CE301296D4FB Q47131193-BEFB258E-6760-4AFE-B699-F255D72A15FD Q50533723-57E03FCC-94F8-49A3-B942-2EC542E7AC31

P2860

Oral bisphosphonate compliance and persistence: a matter of choice?

http://www.wikidata.org/entity/Q34472700

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Oral bisphosphonate compliance and persistence: a matter of choice?

@ast

Oral bisphosphonate compliance and persistence: a matter of choice?

@en

Oral bisphosphonate compliance and persistence: a matter of choice?

@nl

type

label

Oral bisphosphonate compliance and persistence: a matter of choice?

@ast

Oral bisphosphonate compliance and persistence: a matter of choice?

@en

Oral bisphosphonate compliance and persistence: a matter of choice?

@nl

prefLabel

Oral bisphosphonate compliance and persistence: a matter of choice?

@ast

Oral bisphosphonate compliance and persistence: a matter of choice?

@en

Oral bisphosphonate compliance and persistence: a matter of choice?

@nl

P1433

Q34472700-154227B9-6F4F-42BC-9565-80E5B734A7BF

P1476

Q34472700-0D83F400-5A3A-422D-9674-EA8B614521C6

P2093

Q34472700-2030E3B1-2B61-408C-92A6-86C4C4597546

Q34472700-77C82F26-8ADF-49F2-93F7-32CD994CE94C

Q34472700-DFCF80CC-D992-407B-AF0E-820E444E8B1B

P2860

Q34472700-12C13C95-F032-4F41-978D-FDFCAA8DE1F2

Q34472700-14AD2985-50F3-4E25-B4E9-DBAEBCDA7620

Q34472700-17587804-35B5-4FC3-B37B-FB0A396DE22E

Q34472700-1BA06784-D18E-4BBB-909A-6E31F1E7CEAD

Q34472700-2C44345C-2833-4685-AF32-1E2AB73088E4

Q34472700-3196BD46-6D4C-4329-9F21-419FEB081544

Q34472700-4A32D6A3-58E8-47B1-B359-41A76A1C8B8D

Q34472700-4F2B8F38-D796-4E07-B74C-4A58844CEB2E

Q34472700-579462C1-200C-47C6-A8A0-5A326BA1C316

Q34472700-5B485695-8747-47FD-8686-86964BA551D5

P2888

Q34472700-218D3FED-A7B6-4E44-BE33-8CF277E155E9

P304

Q34472700-31A5885F-49EB-4D6C-A508-9F9136D5F8A2

P31

Q34472700-51286483-759A-4006-B08A-E87768D6151F

Q34472700-CB3EBFDA-911C-4E63-92F4-59FE467B72D7

P356

Q34472700-00A8EDB8-4F69-4D68-8427-13D3D6C9009E

P407

Q34472700-B8A29F72-7ABC-4815-8372-F2BCEFBE6CE5

P433

Q34472700-B15C75A1-14B3-4133-867B-587795EA2AD5

P478

Q34472700-D4B1AB78-9046-4D96-AF37-7ED9A98BACEE

P577

Q34472700-A11C6EB0-DE38-439C-B3DE-0BBF55426622

Q34472700-F158E366-ECAA-4F2C-9709-DD5184182436

P5875

Q34472700-89BE37AD-1C21-40F5-AA59-4DF47453F8D3

P698

Q34472700-A24ED0A2-86F5-4DB0-8286-C1E861AF49E1

P921

Q34472700-04B90011-927E-402C-94BC-3DBF15D55FCC

Q34472700-A34CF890-0DF6-4292-AFB4-B52D1C678602

P932

Q34472700-22194D21-4588-4ACB-840E-1D230C04E073

P356

S00198-010-1274-6

P1433

Osteoporosis International

P1476

Oral bisphosphonate compliance and persistence: a matter of choice?

@en

P2093

D T Gold

http://www.w3.org/2001/XMLSchema#string

J T Schousboe

http://www.w3.org/2001/XMLSchema#string

S L Silverman

http://www.w3.org/2001/XMLSchema#string

P2860

Interventions for enhancing medication adherence

Adherence with statin therapy in elderly patients with and without acute coronary syndromes

Adherence to osteoporosis treatments: room for improvement

A study of medication-taking and unobtrusive, intelligent reminding

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study

Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review.

Adherence and persistence: impact on outcomes and health care resources.

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

Patients' preferences for osteoporosis drug treatment: a discrete choice experiment.

A systematic review of persistence and compliance with bisphosphonates for osteoporosis.

P2888

s00198-010-1274-6

P304

21-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00198-010-1274-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44588376

http://www.w3.org/2001/XMLSchema#string

P698

20458571

http://www.w3.org/2001/XMLSchema#string

P921

organophosphorus compound

P932

3017316

http://www.w3.org/2001/XMLSchema#string